Results 1 to 10 of about 387,253 (151)

No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors [PDF]

Frontiers in Immunology, 2022
Axial spondyloarthritis (axSpA) is comprised of ankylosing spondylitis (AS) and non-radiographic axSpA. In recent years, the involvement of the interleukin (IL)-23/IL-17 axis in the pathophysiology of axSpA has been widely proposed.
Hua Zhang, Han-Lei Jiang, Sheng-Ming Dai
doaj   +5 more sources

The Role of IL-23 Inhibitors in Crohn's Disease. [PDF]

J Clin Med, 2023
Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, ustekinumab, a monoclonal antibody targeting the shared p40 component of IL-12/23, is currently approved for the treatment of IBD in patients with disease refractory to ...
Fanizza J, D'Amico F, Lusetti F, Fasulo E, Allocca M, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S, Fiorino G.   +11 more
europepmc   +4 more sources

The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. [PDF]

Musculoskeletal Care, 2022
AbstractBackgroundPsoriatic arthritis (PsA) is a chronic inflammatory arthritis characterised by musculoskeletal and extra‐articular manifestations, most notably psoriasis. While the underlying pathogenetic mechanisms are not yet fully understood, a central role has been identified for the IL‐23/IL‐17 pathway.ObjectivesWe briefly describe the role of ...
Fragoulis GE, Siebert S.
europepmc   +5 more sources

Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials [PDF]

Frontiers in Immunology
BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease that impacts both the skin and joints. Currently, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors have become integral components of PsA treatment regimens.
Shan Gao, Xingxing Xie, Ling Fan, Linyuan Yu   +3 more
doaj   +2 more sources

Comparative efficacy and safety of IL-17 and IL-23 inhibitors for moderate-to-severe psoriasis in Asian populations: a systematic review and meta-analysis [PDF]

BMC Immunology
Background Psoriasis is a chronic inflammatory skin disorder affecting a significant portion of the global population. Biologics targeting the IL-17 and IL-23 pathways are effective in treating moderate-to-severe psoriasis; however, most clinical trials ...
Mohammad Alzghool, Song Jiquan, Musa Bin Bashir   +2 more
doaj   +2 more sources

Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis [PDF]

Frontiers in Immunology, 2023
The risk of infection and malignancy may be a concern for patients with psoriasis receiving interleukin (IL)-17 and IL-23 inhibitors, particularly with long-term treatments.
Shuwei Wu, Shuwei Wu, Yuanyuan Xu, Yuanyuan Xu, Lihua Yang, Lihua Yang, Linghong Guo, Linghong Guo, Linghong Guo, Xian Jiang, Xian Jiang   +10 more
doaj   +2 more sources

Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors. [PDF]

J Clin Med
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by recurrent pustules, erythema, and scaling on the palms and soles, leading to a significantly reduced quality of life. Although PPP shares some immunopathological features with psoriasis vulgaris, it is distinguished by unique genetic predispositions, including a ...
Nam KH, Kim YS.
europepmc   +3 more sources

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study [PDF]

Trials, 2021
Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics.
Lara S. van der Schoot, Juul M. P. A. van den Reek, Lynda Grine, Lisa Schots, Wietske Kievit, Jo L. W. Lambert, Elke M. G. J. de Jong   +6 more
doaj   +2 more sources

Clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis: a systematic review and meta-analysis [PDF]

Frontiers in Pharmacology
BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous manifestations affecting both joints and skin. Interleukin-23 (IL-23) plays a central role in the Th17-mediated inflammatory pathway implicated in PsA pathogenesis ...
Jingxin Zeng, Ling Lin, Wei Li, Xinjing Gao, Qian Li, Xin Zhou, Weiyu Liu, Xuelian Zhong, Yunqing Yang, Xibao Zhang, Quan Luo   +10 more
doaj   +2 more sources

IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors. [PDF]

Ann Rheum Dis, 2021
To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and explore mechanistic links between diseased tissue pathology and clinical outcomes.Twenty-seven active PsA patients were enrolled in an observational/open-label study and underwent biopsies of synovium ...
Nerviani A, Boutet MA, Tan WSG, Goldmann K, Purkayastha N, Lajtos TA, Hands R, Lewis M, Kelly S, Pitzalis C.   +9 more
europepmc   +5 more sources